secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocean Biomedical, Inc. (OCEA)
CIK:        0001869974
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001493152-23-037068
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocean Biomedical acquires 50% of Virion Therapeutics for $4.1M cash or 750k shares
--------------------------------------------------------------------------------

- Acquired 50% ownership in Virion, a clinical-stage T cell immunotherapy company, for $4.1M cash or 750k shares of common stock.
- Virion is enrolling first-in-human Phase 1b study VRON-0200 for chronic HBV; expects first data in next few months.
- Ocean may contribute additional cash/shares to support Virion's clinical trial and R&D, including oncology IND submission within 9 months.
- Director Jerome Ringo resigned on Oct 6, 2023, with no dispute with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869974/000149315223037068/0001493152-23-037068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869974/000149315223037068/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-037068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer